{"id":"fludarabine-bayer","safety":{"commonSideEffects":[{"rate":"60-80","effect":"Myelosuppression (neutropenia, thrombocytopenia, anemia)"},{"rate":"30-50","effect":"Infection"},{"rate":"20-40","effect":"Nausea and vomiting"},{"rate":"20-30","effect":"Fever"},{"rate":"20-30","effect":"Fatigue"},{"rate":"5-10","effect":"Neurotoxicity"},{"rate":"5-10","effect":"Tumor lysis syndrome"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fludarabine is a fluorinated nucleoside analog that is phosphorylated intracellularly and incorporated into DNA, causing chain termination and inhibition of DNA synthesis. It also inhibits ribonucleotide reductase, depleting deoxyribonucleotide pools necessary for DNA replication. These mechanisms preferentially affect lymphoid cells, making it effective in hematologic malignancies.","oneSentence":"Fludarabine is a purine analog that inhibits ribonucleotide reductase and DNA polymerase, leading to DNA strand breaks and apoptosis in rapidly dividing cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:46:37.733Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic lymphocytic leukemia (CLL)"},{"name":"Acute myeloid leukemia (AML)"},{"name":"Non-Hodgkin's lymphoma"}]},"trialDetails":[{"nctId":"NCT02784561","phase":"PHASE4","title":"Study of Busulfan and FLAG Conditioning Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2016-07","conditions":"Leukemia","enrollment":80},{"nctId":"NCT00937625","phase":"PHASE1, PHASE2","title":"T-cell Based Immunotherapy for of Melanoma","status":"COMPLETED","sponsor":"Inge Marie Svane","startDate":"2009-06","conditions":"Melanoma","enrollment":31},{"nctId":"NCT02199301","phase":"NA","title":"Tolerance Induction in Living Donor Kidney Transplantation With Hematopoietic Stem Cell Transplantation","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2011-12","conditions":"End Stage Renal Disease","enrollment":6},{"nctId":"NCT00937300","phase":"PHASE1","title":"T-cell Based Immunotherapy for Head and Neck Cancer","status":"WITHDRAWN","sponsor":"Inge Marie Svane","startDate":"2009-06","conditions":"Squamous Cell Carcinoma, Head and Neck Cancer","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["fludarabine phosphate (Fludara)"],"phase":"marketed","status":"active","brandName":"Fludarabine (Bayer)","genericName":"Fludarabine (Bayer)","companyName":"Chinese PLA General Hospital","companyId":"chinese-pla-general-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fludarabine is a purine analog that inhibits ribonucleotide reductase and DNA polymerase, leading to DNA strand breaks and apoptosis in rapidly dividing cells. Used for Chronic lymphocytic leukemia (CLL), Acute myeloid leukemia (AML), Non-Hodgkin's lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}